Compare IIIN & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IIIN | ZVRA |
|---|---|---|
| Founded | 1953 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 609.9M | 499.9M |
| IPO Year | N/A | 2015 |
| Metric | IIIN | ZVRA |
|---|---|---|
| Price | $33.13 | $8.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.71 |
| AVG Volume (30 Days) | 114.8K | ★ 1.2M |
| Earning Date | 01-15-2026 | 11-05-2025 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | ★ 112.14 | N/A |
| EPS | ★ 2.10 | 0.54 |
| Revenue | ★ $647,706,000.00 | $84,388,000.00 |
| Revenue This Year | $14.97 | $333.25 |
| Revenue Next Year | $7.00 | $43.70 |
| P/E Ratio | $15.82 | ★ $15.61 |
| Revenue Growth | 22.39 | ★ 244.60 |
| 52 Week Low | $22.49 | $6.19 |
| 52 Week High | $41.64 | $13.16 |
| Indicator | IIIN | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 63.13 | 41.56 |
| Support Level | $31.34 | $8.31 |
| Resistance Level | $32.24 | $9.03 |
| Average True Range (ATR) | 0.69 | 0.34 |
| MACD | 0.39 | 0.03 |
| Stochastic Oscillator | 92.04 | 38.46 |
Insteel Industries Inc produces and sells prestressed concrete strand (PC strand) and welded wire reinforcement (WWR). PC strand, a high-strength seven-wire cable, is used to strengthen precast concrete in structures like bridges, parking decks, and buildings, enabling longer spans and slimmer designs. WWR includes engineered structural mesh for primary reinforcement, concrete pipe reinforcement for drainage and sewage systems, and standard WWR for crack control in residential and light commercial construction. The company serves markets in the United States and internationally, with the majority of revenue generated in the United States.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.